Volume 28, Issue 5 e14789
ORIGINAL ARTICLE

Treatment outcome at the pediatric stem cell transplantation center in Syria: A single-center experience

Rawan Al khudari

Rawan Al khudari

Department of Pediatrics, Faculty of Medicine, Children's University Hospital, Damascus University, Damascus, Syria

Search for more papers by this author
Dalal Doba

Dalal Doba

Department of Laboratory, Laboratory in Tishreen Military Hospital, HSCT Laboratory in the National Stem Cell Center (HAYAT), Children's University Hospital, Damascus, Syria

Search for more papers by this author
Amjad Esmandar

Amjad Esmandar

Department of Hematology, BMT Technology in Tishreen Military Hospital, Damascus, Syria

Search for more papers by this author
Maged Kheder

Corresponding Author

Maged Kheder

Pediatrics Hematopoietic Stem Cell Transplantation Center, National Stem Cell Center (HAYAT), Faculty of Medicine, Children's University Hospital, Damascus University, Damascus, Syria

Correspondence

Maged Kheder, Pediatrics Hematopoietic Stem Cell Transplantation Center, National Stem Cell Center (HAYAT), Faculty of Medicine, Children's University Hospital, Damascus University, Damascus, Syria.

Email: [email protected]

Search for more papers by this author
First published: 29 May 2024

Abstract

Background

Hematopoietic stem cell transplantation (HSCT) is a therapeutic approach known for its high success rates in treating various hematologic malignancies, hemoglobinopathies, immune deficiencies, and other disorders. Notably, pediatric HSCT commenced in Syria in 2021 amidst the prevailing crisis. This study aims to assess the demographic and clinical profiles of pediatric patients who underwent stem cell transplantation and to analyze treatment outcomes at Syria's inaugural pediatric HSCT center.

Methods

This study is a single-center retrospective analysis of 25 pediatric patients who underwent HSCT underage of 14 years in the National Stem Cell Center (HAYAT) in Damascus within the period 2021–2023. The databases were created based on data that were collected from patient medical records.

Results

In autologous patients, transplant-related mortality (TRM) was 0%, with 4 (57%) experiencing disease relapse, resulting in the death of one patient. Additionally, 3 (42.8%) of patients remain alive under second-line management. The overall survival rate was 6 (85.7%), and the disease-free survival rate was 16 (88%). In allogeneic patients, TRM was 5.5% (1/18). One allogeneic patient experienced disease relapse and subsequently died. The overall survival rate and disease-free survival rate were 16 (88%).

Conclusions

The objective of this study was to assess the outcomes of pediatric HSCT patients who have undergone transplantation thus far. Given the recent initiation of pediatric stem cell transplantation in Syria, our dataset provides a basis for comparison with international hematopoietic stem cell transplantation centers regarding treatment complications and outcomes, notwithstanding the challenges and crises faced within our country.

CONFLICT OF INTEREST STATEMENT

All authors declared no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.